

**THE FREQUENCY OF THE ANTI GAD ANTIBODY IN A SRI
LANKAN DIABETIC POPULATION**

by

Dr. Maduwantha Roshan Pradeep Hiniduma Liyanage


**THIS THESIS IS SUBMITTED TO
THE UNIVERSITY OF SRI JAYEWARDENEPURA FOR THE
AWARD OF THE DEGREE OF MASTER OF PHILOSOPHY**

ON

30th October 2008

DECLARATION BY CANDIDATE

I hereby declare that the work described in this thesis was carried out by me under the supervision of Dr. Sisira H. Siribaddana and any report on this has not been submitted in whole or in part to any university or any other institution for another Degree/Diploma.




.....
Dr. M.R.P.H. Liyanage



DECLARATION BY SUPERVISOR

I certify that the above statement made by the candidate is true and that this thesis is suitable for submission to the University for the purpose of evaluation.



.....

Dr. Sisira H. Siribaddana

(MBBS, MD)

Consultant Endocrinologist and Physician

Honorary Lecturer Guys, Kings St Thomas School of Medicine

University of London.

Coordinator Bioethics Initiative

Institute of Research and Development

No.762/4B, Pannipitiya Road Battaramulla, Sri Lanka.

Dedicated to my wife Subo, for her love, patience and understanding.

TABLE OF CONTENTS

	Page
LIST OF TABLES	vi
LIST OF FIGURES	vii
LIST OF ANNEXURES	ix
LIST OF ABBREVIATIONS	x
ACKNOWLEDGEMENT	xiii
ABSTRACT	xiv
CHAPTER 1 INTRODUCTION	
1.1 Diabetes mellitus	1
1.2 Classifications of diabetes mellitus	1
1.3 Aetiological classification of disorders of glycaemia	3
CHAPTER 2 LITERATURE REVIEW	
2.1 Epidemiology of diabetes mellitus	6
2.2 Epidemiology of T1DM	7
2.3 Pathogenesis and Natural History of T1DM	10
2.4 Hypothetical stages in the development of autoimmune diabetes	10
2.5 Islets of Langerhan in health and disease	12
2.5.1 Normal pancreatic islets	12
2.5.2 Islets of Langerhan in Disease	14
2.6 Immune response and Insulinitis	15

2.6.1	The clone	16
2.6.2	The Th1/Th2 paradigm	16
2.6.2.1	Mechanism of cell apoptosis	17
2.6.2.2	Evidence of other autoimmune Diseases	18
2.7	The Role of Beta Cell Auto Antigens	19
2.7.1	Major autoantigens	19
2.7.2	Minor autoantigens	19
2.7.3	Shared antigens	20
2.8	GAD Antibodies	21
2.9	Epidemiology of GADA	24
2.10	Other antigens	28
2.10.1	Tyrosine phosphatase (ICA512/IA-2)	28
2.11	Genetic Factors	29
2.12	Environmental Factors	32
2.13	Cow's Milk Protein	35
2.14	Microbial Infections	35
2.15	ENVI 10 Dynamic Module Chart	37
2.16	Latent Autoimmune Diabetes in Adults (LADA)	38
2.17	Islet autoantibodies	39
2.18	BMI	40
2.19	HLA genes	41
2.20	Natural History	42

CHAPTER 3 RESEARCH METHOD

3.1 Objectives	45
3.1.1 General objective	45
3.1.2 Specific objectives	45
3.2 Research design and study setting	45
3.3 Justification of selecting southern suburbs of Colombo for the study	46
3.3.1 Sample density	46
3.3.2 Logistics reasons	46
3.4 Diagnosis of diabetes	47
3.5 Classification into T1DM and T2DM	48
3.6 Inclusion and Exclusion criteria	48
3.7 Ethical Clearance (Annexure 9)	49
3.8 Sample selection	49
3.8.1 Sample size estimation	49
3.9 Selection of study units	50
3.10 Participant recruitment procedure	50
3.11 Patient information form (Annexure 1)	52
3.12 Informed consent (Annexure 3)	52
3.13 Data collection instrument	53
3.13.1 The structured questionnaire (Annexure 6)	53
3.13.2 Identification of variables	53
3.13.3 Formulating questions	53
3.13.4 Steps to improve quality of data and	54

formulation of the questionnaire	
3.13.4.1 Peer review	54
3.13.4.2 Pre-test	54
3.14 Standardization of the interviews and interviewers	54
3.14.1 Interviewer guide	55
3.15 Field work	55
3.16 Anthropometry	55
3.17 Control group	56
3.18 Sample collection	56
3.19 Analysis of GAD autoantibodies	57
3.19.1 Methods of GAD antibody measurements and their relative advantageous	57
3.19.2 Similarities and differences between RBA and TRFIA	60
3.19.3 Time Resolved Fluorescence Immuno Assay	60
3.19.4 Assay Procedure	62
3.19.5 Procedural Notes	64
3.19.6 Quality Control	67
3.20 Analytical Performance Characteristics	67
3.21 Data Analysis	68
3.21.1 Statistical analysis	68

CHAPTER 4 RESULTS

4.1 Recruitment and baseline characteristics	69
4.2 GAD antibodies levels in study population	72
4.3 Gender, Types of diabetes and GADA positivity	75
4.4 GADA distribution, age, age at onset and time since diagnosis	76
4.5 Characteristics of individuals who were positive for GAD antibodies	84

CHAPTER 5 DISCUSSION

5.1 Worldwide prevalence of GADA	90
5.2 Reasons for differences in prevalence	91
5.3 T2DM and GADA	94
5.4 Gender difference in GADA positivity	97
5.5 GAD positivity in normal population	97
5.6 Limitations of the study	98

CHAPTER 6 CONCLUSION **100**

REFERENCES **101**

LIST OF TABLES

Table	Description	Page
1.1	Evolution of Diabetic classification	2
2.1	Frequency of autoantibodies GAD65 and IA-2 in different populations	27
2.2	Viruses as aetiological factors for T1DM Diabetes	37
3.1	Summarizes the 2006 WHO recommendations for the diagnostic criteria for diabetes and intermediate hyperglycaemia	47
3.2	Dilution method for the stock solution	62
4.1	Data of the participants enrolled	69
4.2	Characteristics of T1DM & T2DM	70
4.3	Demographic characteristics of the participants	71
4.4	GADA (kIU/L) distribution in the study group	74
4.5	Age, Gender and mean age and type of diabetes in GADA positive patients	75
4.6	Age categories and GADA+ status in diabetes and controls	76
4.7	GADA positive T1DM, T2DM & Controls patients, clinical characteristics	85
4.8	Comparison of GADA positive and negative patients with T2DM	86
4.9	Comparison of GADA positive and negative patients with T1DM	87
4.10	Comparison of GADA positive and negative participants	88

LIST OF FIGURES

Figure	Description	Page
2.1	Hypothetical islet β -cell mass and stages in the development of autoimmune diabetes	11
2.2	Insulin release from the beta cells	13
2.3	Configuration of GAD molecule	23
3.1	RIA (Radio Immuno Assay)	59
3.2	DELFLA GAD65Ab kit. Preparation of reagents	65
3.3	DELFLA GAD65Ab kit. Summary Protocol Sheet	66
4.1	Histogram of the GADA values	72
4.2	Box-and whisker plot of Log GADA values in the study population	73
4.3	Age at diagnosis (years) and Log GADA values in the study population	77
4.4	Distribution of GADA with Age at Onset of Diabetes	78
4.5	Distribution of GADA with Age at Onset of Diabetes	79
4.6	Months since diagnosis Log GADA values in the study population	80
4.7	Distribution with GADA with Diagnosed Period	81
4.8	Distribution of GADA with Age	82
4.9	GADA positive patients and participants according age (Years)	83

4.10	GADA positive patients according to Age (years) at Diagnosis	84
4.11	LADA patient identified with high GADA	89

LIST OF ANNEXURES

Annexure	Description	Page
1.	Patient information leaflet – English	148
2.	Patient information leaflet – Sinhala	150
3.	Patient Consent Form	152
4.	Consent form – Type 1 Diabetic Study – English	153
5.	Consent form – Type 1 Diabetic Study – Sinhala	154
6.	Structured Questionnaire	155
7.	Principles of the assay	160
8.	Biotin-GAD module	169
9.	Ethical clearance	170
10.	Invitation – Sinhala	171

LIST OF ABBREVIATIONS

ABBOS	Antibodies to Bovine Serum Albumin
ADA	American Diabetes Association
APC	Antigen Presenting Cells
APS	Autoimmune Poly-endocrine Syndrome
BMI	Body Mass Index
CBV	Coxsackie B viruses
CMV	Cytomegalovirus
C-peptide	Connecting peptide
CPH	Carboxy-peptidase H
CVB4	Coxsackie virus B4
DPT	Diabetes Prevention Trial
EBV	Epstein Barr Virus
ELISA	Enzyme Linked Immuno Sorbant Assay
FCPD	Fibro-Calculus Pancreatic Diabetes
GABA	Gamma Amino Butyric Acid
GAD	Glutamic Acid Decarboxylase
GADA	Glutamic Acid Decarboxylase Antibody
GDM	Gestational Diabetes Mellitus
GLUT	Glucose-Transporter
HLA	Human Leukocyte Antigen
HSP65	Heat Shock Protein 65
IA-2	Insulinoma Antigen-2

IA-2A	Insulinoma Associated-2 Antibody
IAA	Insulin Autoantibody
ICA	Islet-cell Antibodies
ICA512/IA-2	Protein tyrosine phosphatase
IDDM	Insulin-Dependent Diabetes Mellitus
IFG	Impaired Fasting Glucose
IFN	Interferon
Ig	Immunoglobulins
IGT	Impaired Glucose Tolerance
IL	Interleukin
INOS	Inducible Nitric Oxide Synthase
IVGTT	Intravenous Glucose Tolerance Test
LADA	Latent Autoimmune Diabetes in Adults
MAP	Mean Arterial Blood Pressure
MHC	Major Histocompatibility Complex
MMDM	Malnutrition Modulated Diabetes Mellitus
MODY	Maturity Onset Diabetes of the Young
MRDM	Malnutrition-related diabetes mellitus
NCCLS	National Committee for Clinical Laboratory Standards
NIBSC	National Institute for Biological Standards and Control
NIDDM	Non-insulin dependent diabetes mellitus
NOD	Non Obese Diabetic
OGTT	Oral Glucose Tolerance Test
OND	Other Neurological Diseases

PDDM	Protein-deficient diabetes mellitus
PERM	Progressive Encephalomyelitis with Rigidity and Myoclonus
PP	Pancreatic Poly peptide
PTP	Protein Tyrosine Phosphatase
RBA	Radio Binding Assay
RIA	Radio Immune Assay
SMS	Stiff-Man Syndrome
T1DM	Type 1 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus
Th1	T Helper 1 Cells
Th 2	T Helper 2 Cells
TNF	Tumor Necrosing Factor
TRFIA	Time Resolved Fluoro Immuno Assay
Type1A DM	Type 1 Autoimmune Diabetes Mellitus
Type1B DM	Type 1 Idiopathic Diabetes Mellitus
UKPDS	UK Prospective Diabetes Study
WHO	World Health Organization
WHR	Waist Hip Ratio

ACKNOWLEDGMENT

Foremost, I must thank my supervisor Dr S. Siribaddana for his personal involvement, responsibility shown and pragmatic appropriacy in supervision of my research. My appreciation reverberate across many other professionals, I must mention the architect of my research Prof. D. Fernando, and Prof. C.B. Sanjeevi, who were instrumental in innumerable ways during my study, their guidance was of immense in completion of this study.

My sincere gratitude goes to Head, Dept. of Anatomy and the chair and the members of the Postgraduate studies, the Dean and the Vice Chancellor of the University of Sri Jayewardenepura. Thank you very much for believing in me all this time.

I sincerely acknowledge the support of Swedish Institute (for research grant), Karolinska institute, Colombo South General Hospital Diabetic clinic, Ratmalana Diabetic registry, Sri Jayewardenepura Hospital, IRD (Institute for Research & Development), my colleagues in clinical practice, IWMI (Anputas and T. Dissanayeke).

I must mention the role of Suranga who helped me with lots of computer skills.

My appreciation goes to the authors of the extensive literature devoted to the research and availability of such work as the founding stone of my study and many others who contributed in various ways.

I must highlight the role of my parents and my family who stood by me and helped me to be what I am; if not for them this thesis would never have been written.

Lastly, my two little sons Dimeetrii and Minain who have contrtributrd lots of their play time to be away from home.

were referred from four centers and 383 (39%) were enrolled in the study. Except the sex and the time since diagnosis, three groups (T1DM=87, T2DM=97 and controls=199) were different in all other factors. Time Resolved Fluoro-Immuno Assay (TRFIA) was used to measure GAD antibodies. Among 383 individuals, 50 (13.1%) were GADA positive. The mean and the median GADA values (ng/ml) in T1DM 204.5 and 14.0 and in T2DM 19.2 and 7.7 and in non-diabetic controls were 33.8 and 9.4.

The prevalence of GADA among T1DM individuals were 23.0% (95% CI: 14.16-31.84), T2DM individuals 11.3% (95% CI 4.77-17.23) and control population 9.5% (95% CI 5.46-13.63). The value of GADA in these participants (who were positive for GADA) is significantly different with highest among T1DM and lowest among T2DM. There is no significant difference between gender and GAD positivity in all 3 groups. GADA +ve patients with T2DM were older and diagnosed later than T1DM patients. GADA values decreased with time since diagnosis in both type1 and type 2 diabetics. 4% of variation in GADA values can be due to age in patients with T1DM. Antibodies to GAD are present in 23.0 % of our patients when compared with 70% of patients with T1DM in Europe. High percentage of T1DM patients with positive family history (28%) may indicate masquerading LADA in T1DM group. In our results higher (9.5%) percentage of the healthy controls being GAD positive is intriguing. This may be due to lower sensitivity of the test. In addition, it may be due to higher background autoimmunity in our sample and population.